Comparison of 10 days of monotherapy with tenofovir alafenamide 8, 25 and 40 mg/day and tenofovir disoproxil fumarate 300mg in patients with HIV-1 infections

Trial Profile

Comparison of 10 days of monotherapy with tenofovir alafenamide 8, 25 and 40 mg/day and tenofovir disoproxil fumarate 300mg in patients with HIV-1 infections

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2015

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 05 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top